Next-Generation Sequencing-Based Multi-Cancer Panel

In The News,

Sep 19 2022

Next-Generation Sequencing-Based Multi-Cancer Panel

Guided a molecular diagnostics company on preparing for commercialization of their multi-cancer panel through clinical evidence review, clinical utility study design, dossier development, value proposition development and validation. Interviews were conducted with ADVI payer – Medicare, Medicaid, commercial – and clinician advisors.